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Abstract: One of the greatest challenges facing the pharmaceutical industry today is the failure of promising new drug 
candidates due to unanticipated adverse effects discovered during preclinical animal safety studies and clinical trials. Late 
stage attrition increases the time required to bring a new drug to market, inflates development costs, and represents a 
major source of inefficiency in the drug discovery/development process. It is generally recognized that early evaluation of 
new drug candidates is necessary to improve the process. Building in vitro data sets that can accurately predict adverse 
effects in vivo would allow compounds with high risk profiles to be deprioritized, while those that possess the requisite 
drug attributes and a lower risk profile are brought forward. In vitro cytotoxicity assays have been used for decades as a 
tool to understand hypotheses driven questions regarding mechanisms of toxicity. However, when used in a prospective 
manner, they have not been highly predictive of in vivo toxicity. Therefore, the issue may not be how to collect in vitro 
toxicity data, but rather how to translate in vitro toxicity data into meaningful in vivo effects. This review will focus on the 
development of an in vitro toxicity screening strategy that is based on a tiered approach to data collection combined with 
data interpretation. 
Keywords: In vitro, predictive, toxicity, screening, hepatocytes, drugs. 
BACKGROUND AND RATIONALE FOR IN VITRO 
TOXICITY SCREENING 
  The discovery and development of a new pharmaceutical 
drug requires more than a billion dollars and can take 12 
years of research effort. The drug development process can 
be divided into four distinct phases: early discovery, late 
discovery, preclinical, and clinical. When a new chemical 
with interesting biological properties enters this process, it 
will undergo extensive testing designed to address and solve 
many complex issues (Fig. 1). New chemical entities or 
NCEs can be dropped from development for many reasons 
during this process, and the attrition rate for NCEs during 
preclinical and clinical studies is higher than it has been in 
decades. Although there are several factors that contribute to 
attrition, two major reasons are efficacy and toxicity (Fig. 2). 
It has been estimated that only 1 of 10,000 chemicals that 
enter the discovery process ever reaches the market. This is 
not hard to imagine when one considers that 40% of NCEs 
that begin preclinical safety studies in animals will fail due 
to toxicity, and that 89% of NCEs that enter clinical trials 
will fail. The greatest cost in terms of time occurs in early 
and late discovery, which can require 6 to 8 years of research 
effort. In comparison, the highest cost in terms of dollars 
occurs in the preclinical and clinical studies. The ability to 
identify and reduce risk early can significantly improve the 
process of drug development by improving efficiency and 
improving the probability of success. 
  The high rate of attrition and the staggering cost of drug 
development mean that better decisions need to be made 
earlier. The evaluation of candidate drugs in animal safety 
studies should provide a means to verify safety, not identify 
toxicity. The new paradigm in drug discovery should include  
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a robust means of identifying issues related to toxicity early 
in the discovery process where the cost of dropping a 
molecule is less than in later phases. The primary objective 
at this stage of development should be the simultaneous 
optimization of desired drug attributes, while at the same 
time identifying potential adverse effects. This approach 
would enable discovery scientists to select candidates for 
preclinical safety trials with the highest probability of 
success. 
  Many believe that the primary goal of the in vitro models 
for evaluating toxicity should be to predict human specific 
toxicity [1]. This may be due in part to the success that in 
vitro screening for certain absorption, distribution, 
metabolism, and elimination (ADME) endpoints has seen 
over the past 10 years. In 1991, the primary reasons for drug 
failure in clinical trials were related to pharmacokinetics and 
bioavailability. These factors accounted for 40% of the drugs 
dropped from development. In vitro systems designed to 
evaluate permeability, interaction with membrane transporter 
systems, and metabolic stability in cell models with human 
relevance reduced this failure rate to less than 10% by 2000 
(Fig. 2) [2]. The administration of one drug can significantly 
alter the plasma concentration, half-life, or toxicity of 
another drug. This Phenomenon is called a drug-drug 
interaction or DDI. Drugs that inhibit cytochrome P450 
(CYP) enzymes, such as CYP3A4, or that can induce the 
production of CYP enzymes have a high probability of 
producing a DDI [3-5]. Because animals have significantly 
different CYP enzymes, gut physiology, and 
pharmacokinetics than humans, new drugs are typically not 
tested in animals under conditions that would reveal 
potential DDIs. Thus, in the case of permeability, 
bioavailability, metabolic stability, and potential DDIs, it 
makes sense to build in vitro screening models focused on 
predicting human outcomes. 
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Fig. (1). Diagrammatic representation of the major steps in the drug discovery process. A typical path for drug discovery is presented. 
Compounds in a chemical library are screened to identify those molecules that interact with the intended target. Molecules that are positive in 
this assay “Hits” begin the process of lead identification (Hit-to-Lead) and Lead optimization. In vitro toxicity screening as well as screens 
designed to identify ADME, genotoxicity, and cardiac toxicity should be done early in this process in order to identify high risk molecules 
early. 
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  The Food and Drug Administration (FDA) requires the 
submission of an Investigational New Drug (IND) package 
prior to manufacturing, transport across state lines, and 
testing in humans. A large part of the IND submission 
consists of animal safety studies. Typically, these studies are 
performed in a rodent (rat) and non-rodent species (dog). 
  Compounds that produce significant toxicity in animal 
models may never be tested in humans because they would 
never be allowed into clinical trials. An exception to this 
would be if the mechanism of toxicity in animals was unique 
to animals and thus not relevant to human safety. A classic 
example of this can be seen with phenobarbital and the 
associated liver enlargement, transient increases in liver 
enzymes in serum, and thyroid effects, which result in 
tumors in rodent carcinogenicity studies. Several studies 
have demonstrated that liver enlargement and development 
of tumors was due to phenobarbital induction of cytochrome 
P450 enzymes, as well as certain phase II conjugating 
enzymes that occur in rodents, but not in humans [6]. Thus, 
drugs and chemicals (e.g., loratadine and oxazapam) that 
display classical phenobarbital-like effects and produce 
tumors in rodents may still be approved by the FDA [7]. 
  Until the FDA changes its process for evaluating the 
safety of new drug candidates, it will be important to 
incorporate cell-based models that can predict toxicity in 
rodents into early higher throughput screening paradigms. 
Then as potential candidates become visible in vitro models 
designed to predict human specific risk can be used. It is 
important to remember that a compound considered to be 
non-toxic in the rat may be toxic in another species including 
humans. One way to approach this challenge is to establish a 
multi-tiered in vitro screening approach designed to identify 
compounds that produce acute, chronic or delayed type 
toxicity in the rat, predict organ specific toxicity, identify 
species-specific toxicity, and determine potential risk factors 
for adverse effects in small patient populations which would 
include risk for idiosyncratic toxicity. 
BUILDING A TIERED TOXICITY SCREENING 
APPROACH 
  The challenge is to incorporate methods for evaluating 
and understanding potential liabilities of NCEs into multiple 
phases of the drug discovery process. It is unlikely that any 
one in vitro model would be sufficient as a final decision 
point for toxicity, but rather a series of models that provide 
important information at the right time in the discovery 
pipeline should be used in a tiered approach (Fig. 3). A well 
defined decision tree should also be part of this screening 
paradigm. In order to be useful, the in vitro toxicity 
screening models must be well characterized and predictive 
of in vivo effects with a low incidence of false positive or 
negative results. The system should have the capacity to test 
a large number of molecules in a short period of time with a 
minimum amount of compound. The data should provide 
information on potential mechanisms of toxicity, and 
subcellular targets. Early in the discovery process, when the 
number of molecules identified as “hits” can be large, in 
vitro cell-based toxicity assays can be used to rapidly assess 
potential safety issues associated with a new group of 
molecules. This information can be used in an iterative 
manner as chemists modify structures to improve drug-like 
properties, the modified compound can be retested for 
toxicity. 
  When the test compounds produce a half-maximal response 
in the cytotoxicity assays a toxicity index or TC50 can be 
determined. A typical early step in drug discovery is to optimize 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). A tiered approach to early toxicity screening. A single in vitro screening platform is unlikely to provide the diverse set of data 
required to evaluate risk and predict in vivo toxicity. Therefore, a tiered systematic approach to in vitro screening should be employed. 
Solubility, protein binding, an understanding of the relationship between potency and toxicity, and the identification of severe toxicity should 
be an early consideration. This is followed by detailed information on the mechanism of toxicity and prediction of toxicity in rodents. The 
identification of compounds that would cause gene toxicity or have a high risk for producing cardiac toxicity should also be determined as 
early as possible. Potential issues related to drug-drug interactions (DDIs) and species-specific toxicity round out the toxicity profile in late 
discovery. Prior to selecting a candidate for preclinical development, the compound should be reviewed in terms of therapeutic area, 
risk/benefit scenarios, and anticipated duration of exposure. In Vitro Predictive Toxicity Screening  Combinatorial Chemistry & High Throughput Screening, 2010, Vol. 13, No. 2    191 
the potency of an NCE for the intended target, which is 
expressed as an IC50. When the toxicity (TC50) value is 
compared to the potency (IC50) value, an in vitro therapeutic 
index is obtained. This ratio can be used to determine the 
relative risk of toxicity between two or more molecules. As 
toxicities begin to emerge it is essential to know whether these 
are an extension of the intended pharmacology (a  target 
mediated effect) or whether they are due to off-target effects 
related to compound chemistry. If the toxicity of an NCE 
increases as potency is improved, the compound has less value 
because these data indicate that the undesired effects are the 
result of target interaction. If, on the other hand, there is a clear 
separation between the two parameters, the molecule holds 
greater promise. When the test compound produces severe 
toxicity in vitro and is anticipated to reach therapeutic plasma 
concentrations that are greater than or equal to the TC50 value 
the probability of in vivo toxicity is high. 
  NCEs that pass through this portion of the funnel begin late 
stage discovery, or lead optimization. Although the placement 
the utilization of specific assays and screens in the discovery 
process can vary, it is typically in this phase where potential 
drug candidates are screened for cardiac toxicity, gene toxicity, 
DDI potential, as well as risk for systemic acute and chronic 
toxicity. In vitro assays must have clear in vivo relevance so that 
discovery scientists have confidence that the effects observed in 
vitro accurately reflect in vivo events. There also must be a clear 
link between the in vitro toxicity data and the in vivo anchor, or 
reference, parameter. One example of an in vivo reference point 
is the plasma concentration attained at the lowest dose that 
produces toxicity in animals following repeated administration 
of the test compound. This parameter may also be used when 
extrapolating  in vitro data to in vivo effects in humans. The 
ability to link in vitro results with in vivo plasma concentrations 
provides a solid reference point for assessing the relative risk for 
toxicity between several NCEs. In vitro assays that can predict 
general toxicity in rat 14-day repeat dose studies are important 
because they provide a means of evaluating in vivo risk relative 
to therapeutic area, potency, and estimated maximum thera-
peutic plasma concentrations. This information is invaluable 
when trying to discern from among a handful of potential 
candidates the one with the most desired drug-like properties 
and lowest risk profile. 
  Once a candidate and possibly a backup are selected for 
preclinical animal safety evaluations, it is important to identify 
and understand potential differences in toxicity between the test 
animals and humans. Early detection of potential species-
specific toxicity issues prior to initiating an animal study can be 
provide valuable information that can be used to select a more 
appropriate test species. Moreover, when the mechanisms 
underlying species-specific toxicity can be elucidated, it is 
easier to provide perspective on what would be expected to 
occur in humans. The pharmacokinetics of a test compound can 
vary between species with clear effects on subcellular targets of 
toxicity, metabolism, the metabolites formed, and half-life. 
When the mechanism(s) of species-specific toxicity can be 
identified and characterized, these data can be used to argue that 
the toxicity observed in one test species is not relevant to human 
risk because the mechanism underlying the animal toxicity is 
not present in humans. 
 
SELECTING THE IN VITRO TEST SYSTEM 
Cell Lines 
  There are many cell and tissue models available for in 
vitro toxicity testing. A prudent approach is to understand 
both the strengths and weaknesses of each model. Early 
discovery screening requires a robust cell model that can be 
easily cultured for 24-72 h in 96 well culture plates. The 
cells should be genetically stable and provide reproducible 
results day-to-day. The cells should be well characterized in 
terms of their doubling time, optimal growth conditions, and 
biochemistry. There are many examples of cell lines that 
have been used to assess toxicity. These include, MDCK, 
Caco, V79, HUH7, HepG2, NRK-52E, 3T3, HEK293, and 
many more. When selecting a cell line as a model system in 
early screening, it is important to fully characterize and 
understand the morphology and biochemistry of the cell, 
including the species and organ from which it was derived. 
  One example of a useful cell model is the rat hepatoma 
(H4IIE) cell line which has several unique properties that 
make it a good choice for in vitro screening. These cells have 
been well characterized in terms of growth properties and 
their biochemistry. They were first introduced in the 1960s 
and have been well described in the literature. Their 
doubling time is approximately 22 h, and they can be 
cultured in a wide range of serum concentrations. The cells 
are sensitive to CYP1A inducers, such as 3-
methylcholanthrene and dioxins, and as such have been used 
in bioassays to detect dioxin like molecules in environmental 
systems [8-11]. The cells possess a complete glutathione 
redox system [12, 13]. Glutathione S-transferase isoforms 
are present in high abundance [14]. The enzymes involved in 
the synthesis of GSH (glutamate-cysteine ligase and GSH 
synthetase) are also present and can be up regulated by 
exogenous chemicals [15]. Many cells in culture lose 
oxidative metabolism and convert to anaerobic metabolism 
(glycolysis) for energy production, a process known as the 
Crabtree effect. H4IIE cells are unique in that they maintain 
oxidative metabolism, a much more in vivo like property 
[16]. These cells also express high levels of P-glycoprotein 
and possess extremely low constitutive drug metabolizing 
activity. The low drug metabolizing activity means that the 
toxicity data obtained represents the effects of the parent 
compound. 
Primary Hepatocyte Cultures 
  Primary hepatocytes from rat, dog, monkey and human 
have been used extensively to evaluate chemical and drug 
toxicity, metabolism, bioactivation, transporter interaction, 
intrinsic clearance, and other biochemical processes [12, 17-
20]. An important advantage of primary hepatocytes is that 
NCEs can be evaluated in vitro with cells prepared from 
normal tissue. This system also provides a convenient means 
of comparing compound toxicity in the same tissue type 
from different species including humans. Because primary 
hepatocytes have both phase I and phase II drug 
metabolizing systems they have been used extensively to 
study drug metabolism, and toxicity. 
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  The use of primary hepatocytes for early higher 
throughput toxicity screening of NCEs is not practical due to 
the need for animals, time for isolation, variability between 
preparations  and cost. The routine use of human primary 
hepatocytes is even less desirable because of limited tissue 
availability, variation in isolation procedures, and inter-
individual variation. The use of cryopreservation 
technologies for long term storage of primary hepatocytes 
provided a significant improvement to this model. 
Cryopreservation of human hepatocytes makes their use 
more feasible for routine screening. Variation between 
donors can be reduced by pooling hepatocytes isolated from 
multiple individuals. This cell system can provide valuable 
information on compound toxicity and metabolism if the 
source and quality of the cells are closely monitored. Day-to-
day variation can be high, and the response and quality of the 
cells can vary greatly from one laboratory to another. 
  Primary hepatocytes grow optimally in the presence of 
serum protein. The cultures can be sensitive to both the 
serum concentration used and the source of the serum used. 
Optimal growth of hepatocytes is usually achieved with 
culture plates that have been coated with an extracellular 
matrix protein, such as Matrigel or collagen. Culture time is 
limited in most laboratories to a maximum of 72 h without 
significant loss of metabolic activity. Cytochrome P450 
activity is typically inducible and present at constitutive 
levels with good metabolic capacity, provided the cells are of 
high quality and are cultured under conditions that optimize 
cell viability and maintain CYP activities. 
  Strict criterion for cell use should be implemented and 
adhered to in order to reduce variability between 
experiments. For example, cells that can not be established 
in monolayer culture may not be considered acceptable for 
use [12]. This cell model can provide important information 
related to species differences in metabolism and toxicity. It 
also provides information on CYP induction, an important 
parameter used to assess a compounds potential for causing 
DDIs. More specialized and complex culture techniques, 
such as sandwich-cultured hepatocytes can provide an in 
vitro model that is capable of identifying more specific types 
of hepatotoxicity, such as damage to bile cannilicular 
membranes known as hepatobiliary toxicity [21]. Human 
bile salt export pumps (BSEP) can be a target for some drugs 
and chemicals; therefore, inhibition of BSEP can result in 
hepatobiliary as well as generalized toxicity [22]. 
Bioactivation of a test compound occurs when metabolizing 
enzymes convert the parent molecule to a more toxic 
metabolite. Primary hepatocytes can be used to identify 
compounds that undergo metabolic activation and to 
determine how these metabolites affect cellular toxicity [23, 
24]. 
Precision Cut Tissue Slice 
  Precision cut tissue slice (PCTS) is a process whereby 
cores of excised tissue, such as liver can be sliced into discs 
of uniform thickness. The tissue slices obtained from this 
process can be incubated with test compounds and the 
effects on various biochemical functions monitored. This 
system has been used to investigate the toxicity of a wide 
range of drugs and chemicals. Both phase I and phase II 
metabolizing systems are intact [25] and inducible in PCTS 
[26]. Some advantages to this system include an intact 
organotypic architecture that is similar in composition to the 
original tissue. Most cell types present in the tissue are 
represented and each cell type can be found in the correct 
relative abundance. This allows evaluation of cell-to-cell 
interactions  in vitro. For example, the effect of a test 
compound on one cell type (e.g., Kupffer) which may be 
stimulated to release mediators, such as cytokines that can 
then act on neighboring parenchymal cells to cause toxicity 
can be monitored [27-31] (Fig. 4). Immunohistochemical 
and histological staining procedures can be used to evaluate 
the effects of compounds on cell health. Systems that require 
cell-to-cell communication, such as the hepatobiliary system, 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Diagrammatic representation of tissue architecture with precision cut tissue slice. The ability to assess whether a new drug candidate 
could produce hepatobiliary toxicity, or toxicity resulting from activation of Kupffer cells and subsequent release of chemical mediators, can 
only be tested in cell models that maintain a cellular architecture similar to the that in vivo. A key advantage of PCTS over primary 
hepatocytes and co-culture models is that the relative abundance of each cell type is maintained. In Vitro Predictive Toxicity Screening  Combinatorial Chemistry & High Throughput Screening, 2010, Vol. 13, No. 2    193 
are also intact in the liver slice model. Thus, PCTS is an 
excellent model for evaluating drug of chemical induced 
hepatobiliary toxicity [32]. Multiple tissues from a single 
animal can be used to prepare slices, and this has been 
successfully done with liver, kidney, heart, and lung tissues 
[33-34]. Not only does this system provide a means of 
comparing compound effects across multiple organs, but it 
also allows for comparisons across multiple species. This 
means that the system can be applied to problems that 
require the ability to discern toxicity, including target organ 
toxicity, and species-specific toxicity [33-36]. 
  One disadvantage of PCTS has been the relatively small 
number of slices that could be obtained from a single animal 
and tissue type making high volume screening less practical. 
However, recent studies by [37] describe a method of 
significantly increasing the number of slices by preparing 
small slices known as “chips”. The use of liver chips has the 
advantage of significantly increasing the number of test 
wells, and hence treatment groups, that can be analyzed. 
Another disadvantage that has limited the use of PCTS as an 
early screening tool has been the inability to cryopreserve 
slices, and to recover them with a high degree of viability. 
Recent efforts to improve cryopreservation techniques in 
different species have demonstrated that it is possible to 
cryopreserve tissue slices [38-40]. While most of the 
cryopreservation work reported has been with liver or kidney 
slices it will be necessary to develop and validate methods 
that can be applied to all tissues from which slices are made. 
Issues of viability related to time in culture, regional changes 
in viability due to the thickness of the slice, diffusion of 
nutrients, and the type of incubator employed for culture [41] 
must be tested and optimized for each laboratory. With 
continued improvements and optimization, PCTS can be an 
important tool in the arsenal available for evaluating the 
toxicity of drugs and chemicals in vitro. 
Important Physical and Chemical Properties In Vitro 
 In  vitro cytotoxicity assays have been used by 
laboratories around the world for several decades. However, 
their ability to predict in vivo toxicity of unknown molecules 
has not been reliable. The term predictive implies that the 
toxicity results obtained in vitro can be related to a value in 
vivo that is indicative of dose limiting toxicity. One obvious 
example would be the use of in vitro data to estimate the 
plasma concentration in a rat 14-day repeat dose study where 
toxicity would be expected to occur. This value would then 
become the threshold for toxicity and would serve as a 
reference point for comparing molecules in a group. 
  There are several reasons why the in vitro cytotoxicity 
assays of the past have not provided a reliable means of 
predicting in vivo toxicity. When single endpoints are used to 
monitor cell viability, such as MTT or membrane leakage 
enzymes, there is a higher incidence of false positive and 
negative data. The use of one or two exposure concentrations 
instead of developing a full concentration response curve 
does not provide the kind of quantitative information 
required to extrapolate the in vitro effects to a relevant in 
vivo reference value, such as a plasma concentration, where 
toxicity would be expected to occur. In many instances the 
exposure concentrations used in vitro have little relevance to 
the maximum plasma concentrations achieved in vivo. Other 
important factors typically not addressed include protein 
binding, metabolic stability, metabolic activation, 
metabolites, temporal relationships, and compound 
solubility. In order for in vitro systems to predict accurately 
what will occur in animal or human systems, all of the 
parameters mentioned above, as well as others, must be 
addressed. 
Evaluation of Multiple Parameters Provides a More 
Accurate Toxicity Assessment 
  Drugs and chemicals can affect cell health at multiple 
levels at varying exposure concentrations and after different 
times of exposure. This means that certain subcellular targets 
such as mitochondrial function may be significantly affected 
before the cell dies and releases marker enzymes for viability 
into the media. This is an important concept when in vitro 
cell based biochemical or molecular data are intended to 
predict toxicity in either animals or humans. An example of 
this type of response profile occurs following a 6 h in vitro 
exposure to the pesticide rotenone, a known mitochondrial 
poison, at concentrations ranging from 0.1 to 100 M (Fig. 
5). 
  The four panels represent commonly used cytotoxicity 
assays in many laboratories and include a membrane leakage 
enzyme (glutathione S-transferase, GST) in panel A, cell 
proliferation in panel B, and two markers of mitochondrial 
function MTT and ATP in panel C. Note that if membrane 
leakage (panel A) was the only marker used to assess 
toxicity, no effect would have been observed following a 6 h 
exposure, a false negative result. If cell mass or cell 
proliferation was the endpoint selected, there would have 
been a modest concentration dependent reduction, but it 
would not be clear whether this was due to cell death or an 
inhibition of cell proliferation. Regardless, the degree of 
toxicity would have been considered low, an incorrect 
conclusion. If the evaluation had been done by monitoring 
changes in ATP or MTT, a pronounced concentration 
response curve would have been observed (panel C). These 
endpoints would have provided a more accurate assessment 
of the toxic liability associated with rotenone; however, it 
would not be apparent from just these data whether the 
effects were due to cell death, changes in cell proliferation, 
or inhibition of the enzymes essential for assay performance. 
By combining several endpoints (panel D) it is possible to 
obtain a more complete toxicity profile of the test compound. 
In the case of rotenone, the mitochondrion is the most 
sensitive target, resulting in loss of ATP and reduced rates of 
cell proliferation prior to cell death, after a 6 h exposure. If 
the exposure time is extended to 24 h there is less resolution 
between the endpoints measured (Fig. 5) [42, 43]. 
  Redundancy in biochemical markers reduces false 
positive and false negative results. For example, the 
commonly used marker of cell health 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazolium bromide (MTT) is reduced by 
metabolic enzymes (reductases) to a blue dye. The viability 
of the cell is directly proportional to the amount of blue dye 
produced. Test compounds that induce or inhibit these 
enzymes could produce erroneous results. Dicumarol is an 
example of a drug in this category [44]. It is also important 
to understand the limitations of each in vitro assay. MTT and 
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toxicity; however, the reductases involved with their 
conversion have been reported to be present in subcellular 
components outside the mitochondria [45]. This implies that 
changes in MTT or Alamar Blue readings may not be 
entirely due to changes in mitochondrial function. To 
improve interpretation of MTT and Alamar Blue data it is 
necessary to determine the role of mitochondrial reduction 
for each cell model. This can be done by monitoring MTT or 
Alamar Blue reduction by the test cells with and without 
antimycin A (10 M), a known inhibitor of mitochondrial 
function. This method was used to demonstrate that the loss 
of Alamar Blue signal following drug exposure was 
primarily due to mitochondrial enzymes [46, 47] in neuronal 
cells. Knowing the true contribution of mitochondrial 
reductases to changes in MTT and Alamar Blue can 
dramatically improve the interpretation, and hence, the 
predictive power of the in vitro data. 
The Importance of Reference Points and Multiple 
Parameters 
  The idea that cells in culture, separated from other cell 
systems and endogenous control mechanisms, can predict the 
toxicity of an unknown substance is like sitting in a boat in 
the middle of the ocean on a cloudy night with no visual 
reference points from which to navigate. Simply growing 
cells, adding test compound and measuring a biochemical 
response does not provide a reference point from which to 
predict in vivo toxicity. In order to interpret in vitro data in a 
manner that will provide the highest predictive power, it is 
necessary to establish reference points both in vitro and in 
vivo. These reference points can then be used to predict in 
vivo toxicity. In vitro reference points with the highest value 
are solubility, metabolic stability, cell death (membrane 
integrity), cell number, solubility, and logP. Some key 
reference points in vivo include maximum plasma 
concentration, solubility, protein binding constants, and 
bioavailability. 
 In  vitro evaluation of the oncology drug velcade 
(bortezomib) demonstrates how important multiple 
parametric analysis is for the correct interpretation of in vitro 
data (Fig. 6A). This drug is a proteosome inhibitor that was 
approved for the treatment of cancer by the FDA [48, 49]. 
The drug inhibits cell proliferation and causes cell death by 
caspase dependent and independent processes [50]. The data 
shown in Fig. (6A,  B) represent the biochemical changes 
observed following a 24 h exposure to concentrations of 
velcade ranging from .001 to 300 M in the rat hepatoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Importance of multiple endpoints, time and concentration-response curves. The toxicity of rotenone was evaluated with the rat 
hepatoma (H4IIE) cell line. Cells were seeded into a 96-well culture plate at a density of 10,000 cells per 100 L of culture medium 
containing 20% serum. Following a 48 h equilibration period, rotenone was added at concentrations ranging from 0 to 100 M and allowed 
to incubate at 37
oC with 5% CO2 for 6 h. These data illustrate the importance of time, concentration-response, and multiple endpoint analysis 
for interpreting in vitro toxicity data. After 24 h, all of the biochemical endpoints respond in a similar manner, and resolution between 
response profiles is difficult. The addition of a shorter exposure time allows separation between the different endpoints. It is clear that 
mitochondrial markers (ATP and MTT) are most sensitive to rotenone. Each point on the graph represents a mean of 4-5 wells. The 
coefficient of variation ranged from 10-15%. In Vitro Predictive Toxicity Screening  Combinatorial Chemistry & High Throughput Screening, 2010, Vol. 13, No. 2    195 
(H4IIE) cells. Following the exposure period, all of the cell 
based assays for cell health (ATP, MTT, Cell mass) are 
maximally affected at the lowest exposure concentration 
with a maximum response of approximately 50% (panel A). 
In comparison, the membrane leakage marker for cell 
viability (glutathione S-transferse (GST)) was essentially 
unchanged. This response profile is a general finger print for 
cytostatic drugs or chemicals. 
  The H4IIE cells double approximately every 22 h and in 
this example the exposure was for 22-24 h. Because of this, a 
test compound that inhibits cell proliferation could not 
achieve more than a 50% response. Therefore, the data in 
Fig. (6A, B) indicate that the velcade potently inhibited cell 
proliferation as determined by both the incorporation of 2’-
bromodeoxyuridine (BrdU), and cell mass at the lowest 
exposure concentration tested. The other cell based assays 
responded in a similar manner, but in this case the loss of 
ATP and MTT was not directly related to mitochondrial 
toxicity or to cell death, but rather to a reduction in cell 
number. When this profile is observed during the in vitro 
testing of compounds it is important to establish the full 
concentration response curve. By lowering the exposure 
concentration range of velcade, the entire response profile 
could be defined (Fig. 6B). Cell viability remained high as 
indicated by the lack of response seen with the membrane 
leakage enzyme GST. It should be evident from this example 
that cell based endpoints, such as ATP depletion or MTT 
reductase activity, without reference points, such as cell 
proliferation and cell death, are considerably more difficult 
to correctly interpret. 
  When a test compound has its’ primary effect on cell 
proliferation, and it is being tested in a proliferating cell line, 
it is important to evaluate the molecule in a normal non-
proliferating cell system to more completely characterize 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). In vitro biochemical toxicity profiles that identify cytostatic drugs. Velcade is a first in class proteasome inhibitor prescribed for the 
treatment of cancer. The drug provides a good example of the importance of reference points for the interpretation of in vitro data. The drug 
was tested in the rat hepatoma (H4IIE) cell line as described under Fig. (5). In panel A, the biochemical cell based markers (ATP, MTT, and 
cell proliferation) appear maximally affected at the lowest exposure concentration. Note that the marker for cell viability (GST leakage) is 
essentially unaffected. In vitro data should be normalized to cell number, thus the fact that all cell based endpoints follow the loss of cell 
number indicates a cytostatic effect. In order to confirm this interpretation, exposure concentrations are reduced in order to define the full 
response curve. In panel B, a classical exposure-response curve was produced. Again, all cell-based markers are dependent on cell number. 
This means that the only true effect on the cells under the conditions tested was on cell proliferation, which is a desirable effect for an 
anticancer drug. If a single marker, such as ATP or MTT had been used, the interpretation would have been that the compound was toxic. If a 
membrane leakage marker had been used, the conclusion would have been that the drug had no toxicity. When cytostatic drugs are identified 
by in vitro tests, it is important to evaluate the drug in a normal non-proliferating cell model. In panel C, velcade was evaluated in rat 
primary hepatocytes. There was no change in cell viability or cell number, but there was a reduction in ATP and MTT indicating effects on 
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potential undesired effects from responses that may be 
desired (Fig. 6C). Note that in normal rat primary 
hepatocytes, which do not undergo extensive cell division, 
there was no effect on cell mass, but there was a 
concentration dependent reduction in ATP and MTT, two 
markers of mitochondrial health. In the case of velcade, 
inhibition of cell proliferation without cell death would be a 
desired response for an oncology drug. Inhibition of cell 
proliferation per se might not be considered a cytotoxic 
effect. However, if normal cell populations that undergo high 
rates of cell division in vivo, such as bone marrow cells, 
were inhibited for a prolonged period, the effects would be 
considered adverse. 
  Another example of the importance of multiple endpoint 
analysis for correct interpretation of in vitro toxicity data can 
be seen with the drug methotrexate, which was intended to 
be used as an antiproliferative for the treatment of cancer. 
The in vitro cytotoxicity data shown in Fig. (7) demonstrate 
that the drug potently inhibits cell proliferation to a 
maximum of 50% without acute cell death. The drug also 
effectively induces apoptosis as determined by caspase 3 
activation. An undesired side effect of this drug is 
mitochondrial damage and oxidative stress leading to liver 
toxicity during therapy [51-53]. In Fig. (7) there is a potent 
concentration-dependent loss in cellular ATP that is 
independent of the reduction in cell number. Although 
methotrexate is an effective antiproliferative drug used to 
treat cancer it may also cause undesired toxicity. Multi-
parametric in vitro assays can provide important clues about 
potential undesired effects. 
  The relative sensitivity of various biochemical endpoints 
can provide important insights into potential subcellular 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). In vitro toxicity profiles produced by methotrexate. Rat hepatoma (H4IIE) cells were used as the test system under the conditions 
described under Fig. (5). Concentration response data, measured with several markers of cell health, show a pronounced reduction in cell 
proliferation. A 50% response is a maximum response given that the exposure time was 24 h and the doubling time for these cells is 22 h. 
Cell viability remains high in the face of inhibited cell proliferation. MTT is dependent on cell number; however, the observed reduction in 
cellular ATP was independent of cell number. If MTT had been the only assay used to assess toxicity, the compound would have appeared 
toxic. If membrane leakage had been used to measure viability, the compound would have shown low toxicity. By combining several key 
endpoints that measure cell health, it is possible to determine the primary effect, most sensitive subcellular target, and intended effect versus 
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targets and mechanisms of toxicity [43]. In addition, the use 
of multiple parameters of cell health can greatly improve the 
interpretation of in vitro cytotoxicity data and reduce the 
incidence of false positive or false negative results. 
Endpoints should provide information on both acute type 
toxicity and delayed or more chronic type toxicity. Some 
types of toxicity require time to develop [54]. Acute markers 
such as membrane integrity, mitochondrial function, and cell 
proliferation must be balanced with chronic indicators of 
toxicity, such as glutathione depletion and lipid- 
peroxidation. 
 In  another  example,  in vitro multi-parametric analysis 
was used to evaluate the relative toxicity of three antifungal 
drugs: ketoconazole, itraconazole, and fluconazole. 
Fluconazole has fewer structural similarities than 
ketoconazole and itraconazole (Fig. 8). Although these drugs 
were developed and marketed at different times, it is useful 
to analyze the compounds as if they had been three new 
NCEs in late stage discovery and only two could be selected 
and brought forward into animal safety studies. In 1995 two 
of the molecules, ketoconazole and fluconazole, were 
evaluated in an in vitro primary hepatocyte system [55]. 
These experiments showed that ketoconazole was 
considerably more cytotoxic than fluconazole at 
therapeutically relevant exposure concentrations. Moreover, 
it was reported that one mechanism of ketoconazole toxicity 
was linked to mitochondrial toxicity [56]. The toxicity 
profiles shown in Fig. (9) compare all three antifungal drugs 
in the H4IIE cell model combined with concentration 
response, and multi-parametric analysis. Ketoconazole 
caused mitochondrial toxicity and reduced the rate of cell 
proliferation. Ketoconazole was the most cytotoxic, with 
fluconazole having the safest profile. The estimated blood 
concentration where toxicity would first be expected to occur 
(Ctox) is also shown in Fig. (9). The predicted toxicity value 
of 55 M obtained from the in vitro model was in close 
agreement with actual rat and human pharmacokinetic and 
toxicity data. Remembering that the toxicity data should only 
be one piece of the information used to select candidates for 
development, it is useful to review the potency/efficacy data 
for the three drugs. For the endpoints of potency/efficacy 
selected, all three drugs were similar. An evaluation of 
ADME data relevant to toxicity such as CYP inhibition 
indicates that ketoconazole and itraconazole are potent 
inhibitors of CYP3A4, the enzyme responsible for a large 
portion of drug metabolism in humans. This means that co-
administration of drugs that are metabolized primarily by 
CYP3A4 (simvastatin, lovastatin, terfenadine, midazolam) 
with ketoconazole or itraconazole can result in clinically 
significant drug-drug interactions (DDIs) [57]. In 
comparison, fluconazole is a weak inhibitor of CYP3A4 and 
would therefore have a lower risk for DDIs when co-
administered with drugs metabolized by CYP3A4. However, 
this compound is a potent inhibitor of CYP2C9 and 
CYP2C19 [57, 58] and therefore drugs that are primarily 
metabolized by 2C9 (phenytoin, warfarin, sulfamethoxazole, 
losartan) and co-administered with fluconazole could also 
produce DDIs. If all of these drugs had been developed in 
the same project, the best molecules for continued 
development would have been itraconazole and fluconazole 
as they carry less risk of toxicity produced by the parent drug 
and lower potential for DDIs. Although there is reason for 
concern regarding potential DDIs with the antifungal 
compounds discussed here, this risk must be weighed against 
the risk of not having an effective treatment for systemic 
fungal infections. 
  In early drug discovery, in vitro evaluations of new drug 
candidates is often met with skepticism because of a fear that 
a compound might be “killed” by a false positive result 
before it has an opportunity to become a drug. Although 
there is some validity to this argument, it is important to put 
in vitro data into context relative to other important pieces of 
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data. A compound that tests with a high degree of toxicity 
must be evaluated relative to other desired drug attributes. 
The investigators must ask whether the toxicity is related to 
potency and hence target mediated or whether the toxicity is 
unique to the chemistry. Is the pharmacophore of the 
molecule the same as the toxicophore? The therapeutic area 
of the compound and risk to benefit rationale must be 
applied. Will the drug be administered for two weeks or for 
the life time of the patient? Is the drug intended to treat a life 
threatening disease or a headache? What is the estimated 
maximum therapeutic plasma concentration during the 
course of treatment? A matrix of this type of information can 
be prepared that will provide a more realistic picture of the 
risk profile for a new drug candidate. 
  In order for in vitro toxicity data to be used in the 
decision making process, it must be complete, mechanism-
based, and reliable with a low incidence of false positive and 
false negative results. Again, in vitro and in vivo reference 
points can greatly improve the predictive power. Terfenadine 
was marketed as seldane, an antihistamine that would not 
cause drowsiness. In January of 1997 the FDA proposed 
removing terfenadine from the market because of potentially 
fatal cardiac effects observed in patients who were also 
receiving other commonly prescribed medications, including 
antifungal agents in the azole class, such as ketoconazole. 
The cardiac toxicity was the result of a drug-drug interaction 
with compounds that have been shown to be potent 
mechanism-based inhibitors of cytochrome P450 (CYP) 
metabolizing enzymes (reviewed by [59]). When terfenadine 
was evaluated in an in vitro model over an exposure 
concentration range of 0 to 300 M for 6 and 24 h, 
significant toxicity was observed (Fig. 10). These data 
indicate that if terfenadine had been evaluated in early 
discovery with an in vitro toxicity model, it might have been 
identified as having substantial toxicity. However, this drug 
made it to market; it passed the preclinical safety studies and 
clinical trials, but caused significant cytotoxicity in vitro, a 
false positive result. 
  Understanding why this compound showed less toxicity 
in vivo than is key to improving the in vitro toxicity 
screening process. Terfenadine undergoes first-pass 
metabolism [60], with a reported bioavailability of less than 
1%. The primary metabolite fexofenadine is not only 
efficacious, but less toxic [61, 62]. The extremely low 
plasma concentration of terfenadine translates to low 
toxicity. Unlike the in vivo situation most cells (including the 
H4IIE cells) in culture have low metabolic capacity. Thus, in  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (9). In vitro toxicity screening differentiates toxicity between drugs in the same class. The antifungal drugs ketoconazole, itraconazole, 
and fluconazole ll have a similar mode of action but were not developed at the same time. If the three molecules had been part of a single 
discovery program, in vitro toxicity screening could have provided important information regarding the relative safety of these drugs. To 
demonstrate this, all three drugs were evaluated in the rat hepatoma (H4IIE) cell line according to conditions described under Fig. (5). Under 
the conditions tested, ketoconazole showed the highest potential to produce toxicity, while fluconazole showed the lowest potential to 
produce toxicity. This interpretation is consistent with clinical observations. Values represent the mean of 4-5 wells. The coefficient of 
variation was between 10 and 15% across the assays. Standard error of the mean bars are not shown for clarity. Ctox = estimated plasma 
concentration at steady state where toxicity would be expected to occur in liver, kidney, bone marrow, or heart. ND = not determined. In Vitro Predictive Toxicity Screening  Combinatorial Chemistry & High Throughput Screening, 2010, Vol. 13, No. 2    199 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (10). In vitro toxicity profile for terfenadine, an example of a 
false positive. Terfenadine produced significant toxicity at both 6 
and 24 h. If this compound had been evaluated in an early discovery 
program, the in vitro data would have indicated toxicity. This 
compound was successful in all IND enabling studies. The reason 
for the low levels of toxicity measured in vivo is first-pass 
metabolism. Terfenadine has a bioavailability of <1% and 
undergoes first-pass metabolism. Thus, in vivo plasma 
concentrations of parent drug are below toxic levels. In vitro, where 
metabolism is low, parent compound can reach concentrations that 
can produce toxicity. 
the in vitro system the parent drug terfenadine remained high 
and toxicity related to ion channel disruption was observed 
(Fig. 10). 
  It is important to know whether a new chemical entity 
tested in vitro is metabolically stable. One way to test this is 
to use microsomes to determine the percent of parent 
remaining after a 30 min incubation of 1 and 10 M drug 
(Fig.  11). Liver microsomes are a convenient way to 
compare the metabolism of a test compound between 
species. Compounds that cause toxicity in vitro, but have 
low metabolic stability, would be flagged as potential false 
positives. Compounds that have low toxicity in vitro, and 
undergo extensive metabolism in vitro, may produce 
significant toxicity in vivo due to formation of reactive 
metabolites. The significance of this in relation to 
terfenadine is even more poignant when one considers that 
although the parent molecule was withdrawn from the 
market, its primary metabolite fexofenadine is currently sold 
as Allegra
®. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (11). Metabolic stability of terfenadine (Seldane). Rat 
microsomes were used to evaluate the metabolic stability of 
terfenadine (Seldane). Microsomes were diluted to a final 
concentration of 0.5 mg/mL in phosphate buffered saline (PBS), pH 
7.3, with NADPH (100 M), and test drug at 1.0 and 10 M. 
Following an incubation of 30 min, the amount of parent drug 
remaining was determined by using LC-MS. The data are expressed 
as the percent of parent remaining (%R). Seldane and midazolam 
are examples of drugs that have low metabolic stability. They are 
subject to first-pass metabolism and typically have low 
bioavailability.  In vitro systems with low metabolic capacity 
evaluate the cytotoxic effects of parent drug. In order to reduce 
misinterpretation of these data, it is important to determine 
metabolic stability. 
Protein Binding and Cytotoxicity 
  The efficacy, toxicity, and half-life of a drug can be 
influenced by the amount and type of its association with 
plasma proteins. Drugs in biological systems exist in two 
forms, protein bound and free. The primary classes of 
proteins with which drugs can be associated are albumin, 
lipoprotein, glycoprotein, and globulins. It is the free portion 
that is available to cells and tissues, and which elicits desired 
or undesired effects. The affinity of a drug for protein 
determines availability. Compounds with low affinity will 
rapidly dissociate from protein to reestablish equilibrium. 
Thus the interaction of most drugs with plasma proteins is a 
dynamic and reversible process, with bound-drug moving to 
the free-drug so rapidly that it is considered, for all practical 
purposes, to be fully available to tissues (Fig. 12). This 
means that the rate of dissociation from protein is not rate 
limiting for organ or cell exposure when equilibrium can be 
rapidly established. This is due to the time required for a 
drug to move from protein-bound to free (milliseconds) 
versus the time required to diffuse into cells (seconds) [63]. 
  The presence of serum protein in the cell culture system 
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vitro toxicity data to in vivo effects for two primary reasons: 
1) cell health and 2) cellular exposure to drug. Obviously, 
under in vivo conditions serum protein is 100%. Typically, in 
vitro systems include 10% fetal bovine serum (FBS) in the 
culture medium. Many cell lines and primary cultures are 
sensitive to the serum concentration and their viability is 
dependent not only on the correct concentration used, but 
also on the source of the serum. Serum should be purchased 
from reputable sources that have a quality control program to 
ensure consistency batch-to- batch. Once a satisfactory lot of 
serum has been identified it is a good practice to purchase it 
in quantity and store frozen in order to maintain the 
consistency of the vitro data. The rat hepatoma cell line 
(H4IIE) can be cultured in serum as low as 2.5% and as high 
as 20%. In general the presence of serum protein is 
beneficial as it not only creates an optimal growth 
environment for the cells, but it can facilitate the solubility 
and hence the cellular exposure of difficult compounds. It is 
important to understand protein binding kinetics of potential 
drug candidates. The ability of a molecule to dissociate (Kd) 
from the protein determines whether protein binding will 
limit exposure. Test compounds with a high percent 
association with protein and a low binding affinity (high Kd) 
readily dissociate and in this case the protein will most likely 
improve solubility and delivery to the cells. In contrast, 
compounds with a high percent association with protein and 
a high binding affinity (low Kd) will be much slower to 
reestablish equilibrium, between free and bound drug and 
protein binding will have a greater influence on cellular 
uptake (Fig. 12). 
  New drug candidates with high affinity protein binding 
are less desirable. In vitro screening data that are negative for 
toxicity should be a flag for potential protein binding. The 
effect of protein binding on cytotoxicity can be addressed by 
conducting a serum titration experiment. The test drug is 
exposed to the cell system in the presence of decreasing 
amounts of serum protein (Fig. 13). A shift in the response 
curve to the left indicates high affinity (low Kd) binding. 
The data for the test compound shown in Fig. (13) indicate 
how the toxicity of a drug that has high binding affinity for 
plasma proteins is controlled by the amount of protein 
present in the in vitro system. 
 
Importance of Exposure Time In Vitro 
  The length of exposure time in vitro can have dramatic 
effects on the toxicity profile for a compound. The goal should 
be to determine an in vivo time point to which the in vitro data 
can be modeled. A standard early toxicity evaluation in 
rodents is the 14-day repeat dose study most often carried out 
in rats. If this model is used as the in vivo reference for in vitro 
toxicity evaluations, then the in vitro data should provide a 
reasonable prediction of general toxicity (liver, kidney, bone 
marrow, heart) based on an in vivo target or reference point, 
such as maximum plasma concentration at the lowest dose 
where toxicity was first observed. The challenge then is to 
determine the exposure time in vitro that would enable a 
prediction of plasma concentration in vivo where toxicity 
occurs. It should also be understood that increasing exposure 
times in vitro can have two effects; one is that the curve does 
not shift in terms of the IC50, but the maximum effect 
achieved at higher exposure concentrations increases, and the 
other is that the entire response curve shifts to the left. 
Increased time usually shifts the toxicity response profile to 
the left in vitro; however in most cases there is a limit to this 
shift. For example, the greatest increase in toxicity (shift to the 
left) occurs between 6 and 24 h and between 24 and 48 h with 
little or no shift between 48 and 72 h. This phenomenon was 
reported by [64] in which sodium arsenite was evaluated for 
toxicity in a human osteogenic sarcoma (U-2OS) cell line. 
Concentration response curves were developed following 24, 
48, and 72 h of exposure. The greatest increase in toxicity was 
observed between 24 and 48 h with only small changes 
between 48 and 72 h. 
 An  in vitro screening program should provide data to 
discovery teams in a time frame of two to three weeks. Thus, 
it is advantageous to establish the in vitro model using the 
shortest exposure time possible. In theory, one could select 
any time as long as the algorithm for predicting the in vivo 
plasma concentration after 14-days of repeated exposure 
corrects for in vitro exposure time. Exposure times greater 
than 24 h are logistically difficult in an early screening 
paradigm. Exposures less than 24 h may not allow enough 
time for toxicity to occur, a situation that could produce a 
large number of false negative results. Each laboratory must 
develop a series of in vitro to in vivo comparison studies that 
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enables the time correction to be determined for the exposure 
time selected. 
  There are instances when shortening or extending the 
exposure time can provide important information regarding 
the mechanism of toxicity or help explain why negative 
effects at 24 h may indicate delayed toxicity, which is not 
observed in a 14-day study, but does appear in 28 or 90-day 
animal studies. 
Design and Interpretation of Retrospective Studies 
 Ideally,  new  in vitro models for predicting in vivo 
toxicity of potential drug candidates should be validated in a 
prospective manner. An unknown molecule is screened in 
the in vitro system, to develop the predictive value, and then 
the molecule is evaluated in vivo to determine the accuracy 
of the in vitro data. In reality, this scenario is almost never 
the case because of the enormous expense and time required 
to generate the amount of data necessary to establish the 
validity of an in vitro system. 
  An alternative approach is to test large numbers of 
approved drugs retrospectively in a blinded manner. It is 
important that these studies are designed in a way that 
reduces bias in the experiment. Drugs from multiple 
therapeutic areas should be selected and if possible this 
should be done by a third party and not by the testing 
laboratory. Testing drugs that are known to cause 
hepatotoxicity and then demonstrating cytotoxicity in a liver 
cell does not confirm the predictive value of the in vitro 
assay. There must be a link to an in vivo parameter, such as 
plasma concentration, in order to consider the results of such 
a study valuable in terms of predicting in vivo toxicity. The 
in vitro data should provide a means by which to make a 
statement about the expected toxicity  in vivo. The in vitro 
data must stand alone and should provide a way to estimate 
what will occur in vivo. The question then is not whether the 
in vitro assay correctly identifies a compound already known 
to be toxic, but rather its ability to predict that an unknown 
molecule will be toxic at relevant plasma concentrations. The 
cell model selected may not allow the detection of specific 
types of toxicity where the mechanism is organ specific. A 
liver cell model may not identify a cardio-toxic compound if 
the mechanism of toxicity is unique to heart tissue. The 
ability to characterize risk for adverse events in animals, as 
well as humans, provides a way forward for early discovery 
teams who are faced with making go-no-go decisions during 
lead optimization. The primary objective is to select a 
candidate with the highest probability of success in 
preclinical and clinical safety studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (13). Effects of protein binding on `in vitro` toxicity. The toxicity of drugs with a high affinity for proteins (low Kd) is affected by the 
amount of protein in the in vitro test system. The response profiles depicted in the graphs demonstrate how the toxicity of a drug can be 
changed by the amount of protein in the test system. Compounds evaluated early in discovery that show low in vitro toxicity in the presence 
of high protein concentrations (>10%) should be tested for protein binding. In the example shown, the test compound was evaluated in the 
presence of 20, 10, and 5% serum. Values represent the mean of 4-5 wells. The coefficient of variation was between 10% and 15% across the 
assays. Standard error of the mean bars are not shown for clarity. 202   Combinatorial Chemistry & High Throughput Screening, 2010, Vol. 13, No. 2  James M. McKim Jr. 
  The results of a large and comprehensive retrospective 
study were recently reported by [54]. The overall objective 
of this study was to “test the hypothesis that clinical 
occurrence of human hepatotoxicity concorded with in vitro 
cytotoxicity assessed in a cell-based model with a novel 
combination of critical features and using HCS.” In this 
study 243 approved drugs were selected based on their 
reported clinical hepatotoxicity and placed into four 
categories: 1) severe hepatoxicity, 2) moderate 
hepatotoxicity, 3) non-toxic, and 4) toxic to organs other 
than liver. The toxicity of each drug was measured in an in 
vitro high content screening (HCS) system to determine if 
the  in vitro toxicity assays could detect and differentiate 
between drugs known to cause differing degrees of 
hepatotoxicity in humans. 
  A human hepatoma cell line (HepG2) was used as the 
test system in this study. Multi-parametric data were 
collected to assess cell health, including calcium, 
mitochondrial membrane potential, DNA content, cell 
number, and plasma membrane permeability. These data 
were collected over several exposure concentrations. The 
exposure time was based on the time that provided the most 
complete concentration response profile and was set at 3 
days (72 h). This study successfully demonstrated the value 
of multiple endpoints, the varying sensitivity of biochemical 
endpoints, and the need for concentration response, and time 
optimization. These conclusions were in agreement with 
those reported previously [42, 43]. A component missing 
from the O’Brien [54] study, is the assessment of multiple 
concentration response curves to develop a single value that 
can be used to predict in vivo responses. The authors do 
assign relative risk to each test compound by developing a 
toxic index (TI). The TI is the ratio of the lowest cytotoxic 
concentration to Cmax and was based on the most sensitive 
endpoint responding at the lowest exposure concentration, 
not on a weighted analysis of all endpoints. This assumes 
that the most sensitive endpoint is the most significant in 
terms of predicting hepatotoxicity. 
  The study does provide a means of assessing the potential 
risk of human hepatotoxicity associated with one drug 
relative to others in the same class. However, the ability to 
discern relative risk between molecules must be based on a 
combination of important information sets. The in vitro 
toxicity profiles evaluated against or with therapeutic plasma 
concentrations, length of exposure, and the therapeutic 
risk/benefit value of the drug. The values selected for Cmax 
may not be the maximum plasma concentrations achieved 
during therapy in the clinic or the sources used to obtain 
Cmax data may be in error. For example, azathioprine is 
used as an immunosuppressant to manage inflammatory 
disease processes. The compound is known to produce 
myelotoxicity and hepatotoxicity at therapeutic 
concentrations [65]. The maximum therapeutic plasma 
concentrations reached during therapy is approximately 5-7 
M, a much different exposure scenario than the 0.34 M 
Cmax value reported and used to calculate the TI [54]. 
  The HCS method for assessing the hepatotoxicity of 
drugs was compared to a panel of standard cell based 
cytotoxicity assays performed independently, such as 
membrane integrity, DNA synthesis, protein synthesis, 
glutathione depletion, superoxide secretion, and caspase-3 
activation. When azathioprine was evaluated no toxicity was 
detected in the standard cell-based assays [54]. These 
findings are inconsistent with those reported by several other 
laboratories where significant mitochondrial toxicity and 
depletion of cellular ATP following in vitro exposure of 
various hepatic cell lines to azathioprine at exposure 
concentrations and time similar to those reported [54] (Fig. 
14) [65-69]. 
  Rotenone is a well characterized mitochondrial poison 
that causes pronounced toxicity in cells [43]. Although the 
toxicity of rotenone was identified by HCS in the O’Brien 
[54] study, the compound was not evaluated in conventional 
or standard cytotoxicity assays in this study [54]. Finally, the 
ability to resolve risk between drugs with similar TI values, 
but with different risk profiles, such as paroxetine TI=4, 
acetaminophen TI=4, and cerevastatin TI=3 also requires 
further consideration. Thus, there does not appear to be a 
clear advantage between the HCS method and the use of 
standard cell based assays that monitor toxicity. The point 
here is that multiple endpoints can and do improve the 
predictive power of the in vitro system and that the method 
or platform used to collect data is not nearly as important as 
the process used to interpret the meaning of the data. 
  The predictive power of in vitro screening is improved 
with the inclusion of endpoints associated with chronic 
toxicity. If these endpoints are affected in a concentration -
dependent manner by drugs that have been withdrawn from 
the market due to unanticipated adverse events, but not by 
drugs in the same class considered to be safe, the 
information can provide risk profiles for predicting this 
toxicity. 
  An analysis of several drugs removed from the market 
because of hepatotoxicity revealed that at least three key 
parameters were affected: ATP, GSH, and apoptosis. One 
example of this can be seen with a group of antibacterial 
drugs known as the fluoroquinolines. Two members of this 
group (grepafloxacin and trovafloxacin) were withdrawn 
from the market due to unanticipated toxicity in some 
patients. The acute toxicity markers (membrane integrity, 
mitochondrial function, and cell proliferation) for these two 
drugs showed only a small reduction. All of the drugs in 
class would have been predicted to be safe based on the in 
vitro toxicity data and acute markers. By evaluating markers 
associated with more chronic toxicity, it was shown that the 
two drugs withdrawn caused small reductions in ATP, and a 
pronounced loss in cellular GSH levels. The changes in 
biochemical function were supported by changes in gene 
expression profiles [70]. This relationship between ATP, 
GSH, and apoptosis with idiosyncratic liver toxicity has also 
been demonstrated with other drug groups, such as the 
glitazones, and statins where some members have been 
shown to produce liver toxicity in a small number of 
patients. 
  In order for in vitro biochemical readouts of toxicity to 
be predictive of in vivo effects, many parameters must be 
optimized. In our laboratory the predictive power of the in 
vitro data is greatly improved by evaluating metabolic 
activation, metabolic stability, and CYP induction. Simply 
collecting  in vitro cytotoxicity data is not sufficient for 
careful evaluation of risk around promising new drug 
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vitro toxicity evaluations. In early discovery, emphasis is 
placed on providing data that help predict whether a 
compound will be toxic in rats during 14-, 28-, or 90-day 
repeat dose safety studies. Ideally, an estimate of the blood 
concentration where dose limiting toxicity would first be 
expected to occur is most useful. This information can help 
scientists understand how toxicity and potency are related 
and provide a risk profile for a group of molecules in the hit-
to-lead and lead optimization phase of drug discovery. This 
information can also provide a means of estimating an in 
vitro margin of safety. A margin of safety and a risk/benefit 
assessment can be determined by comparing the estimated 
plasma concentration where toxicity would be expected to 
occur, to the maximum therapeutic concentration anticipated 
during a course of therapy. 
  In the study depicted in Fig. (15), 150 approved drugs 
were selected by a third party and presented in a blinded 
manner for evaluation in a panel of biochemical assays 
(CeeTox Panel
®). The intent of this study was to compare an 
estimated plasma concentration (Ctox) where toxicity would 
be expected to occur in rat 14-day repaeat dose studies, 
derived from the in vitro data, to the maximum therapeutic 
plasma concentration (MTPC) achieved during the course of 
therapy in the clinic. The diagonal red line depicts the point 
where the predicted toxicity value (Ctox) is equal to the 
MTPC. Most approved drugs should not reach plasma 
concentrations that are greater than this predicted threshold 
for toxicity. Clearly, most of the drugs (97%) fall to the left 
of this line. Those compounds that have MTPCs that meet or 
exceed this line of equivalence are in some cases drugs that 
are known to cause toxicity under therapeutic conditions, 
such as azathioprine. What about false positives? If the drugs 
in Fig. (15) had been evaluated in an in vitro toxicity 
screening program early in the drug discovery process those 
with predicted toxicity values (Ctox) of 20 M or less would 
have been considered to have a high probability of causing 
toxicity in animal studies. As expected the majority of 
approved drugs have estimated toxicity values greater than 
20 M. However, some would have been identified as toxic 
by the in vitro system (Fig. 15, red circle). Unmasking some 
of these molecules reveals that an important factor to be 
considered for continued development of NCEs lies in the 
intended use of the drug (risk/benefit), its potency, and, 
margin of safety. 
  Paroxetine is a highly prescribed drug with relatively few 
incidences of toxicity in the clinic. This compound did 
produce cytotoxicity in vitro with a predicted Ctox value of 
15 M. The primary reason for the high degree of safety in 
the clinic is due in part to the high potency and hence lower 
MTPC (0.3 M) reached during treatment. By comparing the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (14). In vitro cytotoxicity of azathioprine. Rat hepatoma (H4IIE) cells were exposed to azathioprine as described under Fig. (5). The 
most sensitive subcellular endpoint was depletion of ATP and this is consistent with reports from other laboratories. This compound is highly 
toxic and is known to cause toxicity in patients during therapy. Values represent the mean of 4-5 wells. The coefficient of variation was 10-
15% across the assays. Standard error of the mean bars were omitted for clarity. 204   Combinatorial Chemistry & High Throughput Screening, 2010, Vol. 13, No. 2  James M. McKim Jr. 
estimated plasma concentration for toxicity (Ctox) to the 
MTPC an in vitro margin of safety can be developed. The 
data in Fig. (15) indicate that as a compound’s MTPC 
approaches the predicted toxicity value (diagonal red line) 
the probability of toxicity increases and the margin of safety 
decreases. 
  It should also be noted that most of the drugs tested have 
MTPC values between 0.1 and 10 M. This indicates that in 
vitro exposure concentrations that range from 0.1 to 300 M 
cover a range of concentrations that are therapeutically 
relevant. These data indicate that the predicted threshold for 
toxicity  in vivo, determined using the CeeTox Panel, does 
provide information about human risk. 
  Discovering that a new drug candidate has no significant 
toxicity in rats, but causes mortality in dogs is a costly 
finding when discovered during preclinical animal studies. In 
most instances species-specific toxicity is related to 
pharmacokinetic or pharmacodynamic differences. Species-
specific toxicity can be addressed with in vitro systems that 
allow direct species comparisons, such as primary 
hepatocytes and liver microsomes from rat, dog, and human. 
Metabolic capability and metabolite profiles are important 
parameters. If a metabolite is responsible for the observed 
toxicity in one species and that metabolite is not formed in 
the species resistant to toxicity the mechanism underlying 
the species-specific toxicity can be resolved. 
  In conclusion, the evaluation of adverse effects and the 
development of toxicity profiles around new chemical 
entities can greatly improve the selection process of new 
drug candidates. This in turn should reduce compound risk 
and increase the probability of success during preclinical 
animal studies and clinical trials. Ideally, early screening 
programs should begin during the hit-to-lead phase and 
continue through candidate selection. A decision tree that 
incorporates physical chemical, ADME, potency, protein 
binding, and toxicity should be developed and adhered to 
during the discovery process. Multiple endpoint analysis, 
concentration response curves, temporal relationships, 
metabolic stability and metabolic activation are essential to 
building a robust screening program. The platform used to 
collect the data is not as important as the quality of the data 
and the process used to interpret the data. In vitro toxicity 
data should be linked to an in vivo parameter that can be 
easily measured and is closely associated with toxicity. In 
vitro toxicity data should not be viewed in isolation, but 
rather combined with other key parameters and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (15). In vitro toxicity screening data combined with clinical data show good concordance. In this experiment, 150 approved drugs were 
selected and analyzed in a blinded manner. The aim of the study was to determine the relationship between the estimated plasma 
concentration where toxicity would be expected to occur in rat 14-d repeat dose studies (Ctox), and the maximum therapeutic plasma 
concentration (MTPC) achieved during the course of therapy in humans. The diagonal red line represents the threshold of toxicity where the 
estimated plasma concentration for toxicity is equal to the maximum plasma concentration measured in humans. If the Ctox value has any 
relationship to MTPC, most approved drugs should not exceed this threshold value. The data above indicate that 97% of the approved drugs 
do not achieve plasma concentrations equal to or greater than the predicted level of toxicity. If the drugs tested had been screened for toxicity 
early in their discovery life-cycle, those that had estimated plasma concentrations for toxicity that fell below 20 M would have been flagged 
as toxic. The horizontal red line depicts this point on the graph. Most of the approved drugs are above this line, however some fall below, and 
therefore might be considered false positives in the in vitro screen. Upon closer inspection, these compounds all have been associated with 
toxicity in human patients. The key to why these drugs are still used in the clinic is related to their potency, in vitro margin of safety, and 
risk/benefit analysis. It is clear that as drug plasma concentrations approach the threshold value (Ctox) of toxicity the probability of an 
adverse event increases. This graph was developed by Dr. Georgor Zlokarnik and the work was part of a collaborative research project 
between CeeTox, Inc. and Vertex Pharmaceuticals. In Vitro Predictive Toxicity Screening  Combinatorial Chemistry & High Throughput Screening, 2010, Vol. 13, No. 2    205 
characteristics of a successful drug in order to make the most 
informed selection of new drug candidates. 
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